Paradoxical counteraction by imatinib against cell death in myeloid progenitor 32D cells expressing p210BCR-ABLMorichika Takita(Tokyo Women's Medical University), Yoshiro Maru(Tokyo Women's Medical University)OncotargetAugust 3, 201810.18632/oncotarget.25849Cited by 4SaveCiteExport RISWatch citationsRelated PapersNovel multivalent S100A8 inhibitory peptides attenuate tumor progression and metastasis by inhibiting the TLR4-dependent pathway|Cancer Gene Therapy|2023|12Novel multivalent S100A8 inhibitory peptides attenuate tumor progression and metastasis by inhibiting the TLR4-dependent pathway|Research Square|2022|1